Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis

Página do item simplificado
dc.creatorMariana Lourenço Freire
dc.creatorGlaucia Fernandes Cota
dc.creatorTália Machado de Assis
dc.creatorEdward Oliveira
dc.creatorDaniel Moreira de Avelar
dc.creatorIsadora Cristina de Siqueira
dc.creatorAldina Barral
dc.creatorAna Rabello
dc.date.accessioned2024-12-06T10:25:39Z
dc.date.accessioned2025-09-09T01:32:27Z
dc.date.available2024-12-06T10:25:39Z
dc.date.issued2019-07-18
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.mimetypepdf
dc.identifier.doi10.1371/journal.pntd.0007484
dc.identifier.issn1935-2735
dc.identifier.urihttps://hdl.handle.net/1843/78488
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPLOS Neglected Tropical Diseases
dc.rightsAcesso Aberto
dc.subjectLeishmaniose Visceral
dc.subjectTestes Sorológicos
dc.titlePerformance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis
dc.typeArtigo de periódico
local.citation.epage12
local.citation.issue7
local.citation.spage1
local.citation.volume13
local.description.resumoBackground: Visceral leishmaniasis (VL) is the most severe form of leishmaniasis and is potentially fatal if not diagnosed and treated. Accurate and timely diagnosis is considered one of the pillars needed for the reduction in disease-related lethality. Brazil is currently one of the three eco-epidemiological hotspots for this disease. Several serological tests are commercially available in this country for VL diagnosis, although information on the performance of these tests is fragmented and insufficient. The aim of this study was to directly compare the performance of six commercial kits: three enzyme-linked immunosorbent assays (ELISAs), two immunofluorescence antibody tests (IFATs), one immunochromatographic test (ICT), besides one ICT, currently not commercially available in Brazil and one in-house direct agglutination test (DAT-LPC), not yet marketed. Methodology/Principal findings: A panel of 236 stored samples from patients with clinically suspected VL, including 77 HIV-infected patients, was tested. IT-LEISH and DAT-LPC showed the highest accuracy rate among the non-HIV-infected patients, 96.2% [CI95%: 92.8–99.7%] and 95.6% [CI95%: 91.9–99.3%], respectively. For the ELISA tests evaluated, the maximum accuracy was 91.2%, and in the inter HIV-status group analysis, no significant differences were observed. For both IFATs evaluated, the maximum accuracy was 84.3%, and a lower accuracy rate was observed among the HIV-infected patients (p = 0.039) than among the non-HIV-infected patients. The DAT-LPC was the most accurate test in the HIV-infected patients (p≤0.115). In general, no significant difference in accuracy was observed among the VL-suspected patients stratified by age. Conclusions/Significance: In summary, the differences in the performance of the tests available for VL in Brazil confirm the need for local studies before defining the diagnostic strategy.
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007484

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis.pdf
Tamanho:
485.15 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG